Ligand Pharmaceuticals LGND Evomela — Total revenue and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's evomela — total revenue and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's evomela — total revenue and income?
- Ligand Pharmaceuticals (LGND) reported evomela — total revenue and income of $1.49M in Q4 2025.
- How has Ligand Pharmaceuticals's evomela — total revenue and income changed year-over-year?
- Ligand Pharmaceuticals's evomela — total revenue and income decreased by 31.5% year-over-year, from $2.17M to $1.49M.
- What is the long-term trend for Ligand Pharmaceuticals's evomela — total revenue and income?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's evomela — total revenue and income has grown at a -12.4% compound annual growth rate (CAGR), from $10.08M to $5.94M.
- What does evomela — total revenue and income mean?
- This metric represents the aggregate financial inflows generated by the Evomela product line, encompassing both recurring royalty streams and associated income. It serves as a primary indicator of the commercial performance and market adoption of this specific pharmaceutical asset within the company's portfolio.